IDYA241220C20000
- 0.00
- 0.000.00%
IDEAYA Biosciences Newsroom
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Stephens Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $51
IDEAYA Biosciences Analyst Ratings
Stephens & Co. Initiates Coverage On IDEAYA Biosciences With Overweight Rating, Announces Price Target of $51
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
IDEAYA Biosciences: Strategic Initiatives and Growth Potential Reinforce Buy Rating
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $64
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $61
IDEAYA Biosciences Analyst Ratings
BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Promising Developments and Strong Financial Position Drive IDEAYA Biosciences Buy Rating
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
Oppenheimer Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $53
IDEAYA Biosciences Price Target Maintained With a $53.00/Share by Oppenheimer
IDEAYA Biosciences Analyst Ratings
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65